Clinical Trial Update: N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating N-803 combined with PD-L1 t-haNK and bevacizumab for recurrent or progressive glioblastoma, whic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• N-803 (Anktiva) (N-803)
• PD-L1 t-haNK

Snippet

Sponsor: ImmunityBio, Inc. | Conditions: Glioblastoma | Phase 2 | Status: RECRUITING